BioSpace News Archive

Maravai LifeSciences Holdings, Inc., a global provider of life science reagents and services to researchers and biotech innovators, reported financial results for the second quarter ended June 30, 2021, together with other business updates.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and six-months ending June 30, 2021 and provided a corporate update.

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced financial results for the second quarter ended June 30, 2021, as well as business highlights.

POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the completion of enrollment and initial dosing of the 25-patient safety and dosimetry lead-in of the Company’s Phase 3 SPLASH study evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Sientra, Inc., a medical aesthetics company exclusively focused on plastic surgery, announced its financial results for the second quarter ended June 30, 2021.

Inari Medical, Inc. a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, reported financial results for its second quarter ended June 30, 2021.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced topline results from the multi-center, randomized, double-blind, placebo-controlled Phase 1a/1b clinical study of CB4211, under development for nonalcoholic steatohepatitis (NASH) and obesity.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the second quarter ended June 30, 2021.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced second quarter 2021 results and provided a corporate update.